[go: up one dir, main page]

WO2007021853A3 - Neuregulin1-stimulated cell adhesion and cell migration - Google Patents

Neuregulin1-stimulated cell adhesion and cell migration Download PDF

Info

Publication number
WO2007021853A3
WO2007021853A3 PCT/US2006/031217 US2006031217W WO2007021853A3 WO 2007021853 A3 WO2007021853 A3 WO 2007021853A3 US 2006031217 W US2006031217 W US 2006031217W WO 2007021853 A3 WO2007021853 A3 WO 2007021853A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
lymphocyte
chemotaxis
migration
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/031217
Other languages
French (fr)
Other versions
WO2007021853A2 (en
Inventor
Daniel R Weinberger
Christopher G Kanakry
Renee Ren-Patterson
Yoshitatsu Sei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2007021853A2 publication Critical patent/WO2007021853A2/en
Publication of WO2007021853A3 publication Critical patent/WO2007021853A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention includes methods for detecting or measuring lymphocyte chemotaxis comprising detecting or measuring the migration of lymphocytes in a direction toward an increased level of a chemoattractant, wherein said chemoattractant is neuregulin1 (NRG1) or epidermal growth factor (EGF)-like domain thereof or derivatives or analogs thereof, wherein the presence and amount of said migration of lymphocytes indicates the presence and amount, respectively, of lymphocyte chemotaxis. Also included are methods of diagnosing schizophrenia and other brain disorders that involve genetic defects in NRG1 signaling pathways and cancers that involve overexpression of ErbB/Her receptors, methods for identifying lymphocyte chemoattractants and tumor-derived cell chemotaxis antagonists and methods of making lymphocyte chemoattractants and tumor-derived cell chemotaxis antagonists. The invention also includes methods for detecting or measuring lymphocyte adhesion involving NRG1 or EGF-like domain thereof and methods of diagnosing schizophrenia and other brain disorders employing the measurement of lymphocyte adhesion obtained from such patients.
PCT/US2006/031217 2005-08-12 2006-08-11 Neuregulin1-stimulated cell adhesion and cell migration Ceased WO2007021853A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70771405P 2005-08-12 2005-08-12
US60/707,714 2005-08-12
US73535305P 2005-11-10 2005-11-10
US60/735,353 2005-11-10

Publications (2)

Publication Number Publication Date
WO2007021853A2 WO2007021853A2 (en) 2007-02-22
WO2007021853A3 true WO2007021853A3 (en) 2007-06-21

Family

ID=37492181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/031217 Ceased WO2007021853A2 (en) 2005-08-12 2006-08-11 Neuregulin1-stimulated cell adhesion and cell migration

Country Status (1)

Country Link
WO (1) WO2007021853A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239697A2 (en) * 1986-03-20 1987-10-07 Costar Corporation Apparatus for growing tissue cultures in vitro
US5139951A (en) * 1990-10-10 1992-08-18 Costar Corporation Culture device having a detachable cell or tissue growth surface
WO2002048191A2 (en) * 2000-12-11 2002-06-20 Yeda Research And Development Co. Ltd. Inhibitory agents derived from specific growth factors
WO2003020911A2 (en) * 2001-09-05 2003-03-13 Decode Genetics Ehf. Human schizophrenia gene

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239697A2 (en) * 1986-03-20 1987-10-07 Costar Corporation Apparatus for growing tissue cultures in vitro
US5139951A (en) * 1990-10-10 1992-08-18 Costar Corporation Culture device having a detachable cell or tissue growth surface
WO2002048191A2 (en) * 2000-12-11 2002-06-20 Yeda Research And Development Co. Ltd. Inhibitory agents derived from specific growth factors
WO2003020911A2 (en) * 2001-09-05 2003-03-13 Decode Genetics Ehf. Human schizophrenia gene

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOYDEN S: "The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes.", THE JOURNAL OF EXPERIMENTAL MEDICINE. 1 MAR 1962, vol. 115, 1 March 1962 (1962-03-01), pages 453 - 466, XP002412197, ISSN: 0022-1007 *
HIJAZI M M ET AL: "HEREGULIN REGULATES THE ACTIN CYTOSKELETON AND PROMOTES INVASIVE PROPERTIES IN BREAST CANCER CELL LINES", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 17, no. 4, October 2000 (2000-10-01), pages 629 - 641, XP008038554, ISSN: 1019-6439 *
KAINULAINEN V ET AL: "A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis", JOURNAL OF BIOLOGICAL CHEMISTRY 24 MAR 2000 UNITED STATES, vol. 275, no. 12, 24 March 2000 (2000-03-24), pages 8641 - 8649, XP002412059, ISSN: 0021-9258 *
LUPU R ET AL: "The significance of heregulin in breast cancer tumor progression and drug resistance", BREAST CANCER RESEARCH AND TREATMENT, vol. 38, no. 1, 1996, pages 57 - 66, XP002412060, ISSN: 0167-6806 *
MORATZ CHANTAL ET AL: "In vitro and in vivo assays of B-lymphocyte migration.", METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.) 2004, vol. 271, 2004, pages 161 - 171, XP008073014, ISSN: 1064-3745 *

Also Published As

Publication number Publication date
WO2007021853A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
Hansen et al. Pacsin 2 is recruited to caveolae and functions in caveolar biogenesis
Haines et al. Regulated expression of FLRT genes implies a functional role in the regulation of FGF signalling during mouse development
DE69738362D1 (en) Leveling monitoring method with improved accuracy for an elevator car
ATE516742T1 (en) METHOD FOR DETERMINING THE OPTICAL PROPERTIES OF A MULTI-LAYER TISSUE
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
ATE310955T1 (en) COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CHEMOKINE RECEPTOR-RELATED DISEASES
ATE262040T1 (en) METHODS FOR DETERMINING RECEPTOR ACTIVITY AND CONSTRUCTS USABLE THEREFOR
ATE502119T1 (en) METHOD FOR EVALUATION OF PATHOLOGICAL DISEASE CONDITIONS USING EXTRACELLULAR RNA
WO2009118205A3 (en) Biomarkers for monitoring or predicting the treatment of cancer
WO2009126380A8 (en) Methods and compositions for highly sensitive detection of molecules
CN107285152A (en) code segment mark
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
EP2071333A3 (en) Method of selectively assaying adiponectin multimers
ATE530635T1 (en) METHOD AND QUANTIFICATION ASSAY FOR DETERMINING C-KIT/SCF/PAKT STATUS
DE69842017D1 (en) PROCEDURE FOR EARLY DETECTION OF DISEASES
WO2008090319A3 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
EP1402276A4 (en) Method of determining when electrode pads are unsuitable for use by detecting relative humidity
ATE342056T1 (en) USE OF INHIBITORS FOR THE TREATMENT OF RTK HYPERFUNCTIONAL DISORDERS, PARTICULARLY CANCER
WO2008110593A3 (en) Method and markers for the diagnosis of renal diseases
Belgore et al. Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, flt‐1, in haematological cancers: A comparison with breast cancer
WO2007021853A3 (en) Neuregulin1-stimulated cell adhesion and cell migration
Anderson et al. Molecular analysis of axon repulsion by the notochord
WO2006113210A3 (en) Diagnostic multimarker serological profiling
Kawano et al. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06801152

Country of ref document: EP

Kind code of ref document: A2